Association of Anti-Diabetic Medications Targeting the Glucagon-Like Peptide-1 Pathway and Heart Failure Events in Patients with Diabetes

摘要

BackgroundGlucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors (GLP-1 agents) may be protective in heart failure (HF). We set out to determine whether GLP-1 agent use is associated with HF risk in diabetics.